Sign In
Buy TAK
$17.09
-0.160 (-0.93%)
At Close: Jul 31, 2026
Takeda Pharmaceutical Company Limited (TAK) Q1 2027 Earnings Call Transcript
12:13pm, Thursday, 30'th Jul 2026
Takeda Pharmaceutical Company Limited (TAK) Q1 2027 Earnings Call Transcript
Takeda Pharmaceutical Q1 Earnings Call Highlights
08:04am, Thursday, 30'th Jul 2026
Takeda Pharmaceutical NYSE: TAK said its first-quarter fiscal 2026 results were in line with its full-year outlook as growth from core brands and newer products largely offset expected declines in its
Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track
02:37am, Thursday, 30'th Jul 2026
OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) announced financial results for the first quarter of fiscal year 2026 (April 1, 2026 to June 30, 2026), marking a period of disciplined exec
Arrowstreet Capital Limited Partnership Sells 2,566,536 Shares of Takeda Pharmaceutical Co. $TAK
03:26am, Tuesday, 28'th Jul 2026
Arrowstreet Capital Limited Partnership trimmed its position in shares of Takeda Pharmaceutical Co. (NYSE: TAK) by 45.2% during the undefined quarter, according to its most recent 13F filing with the
Comparing Medicure (OTCMKTS:MCUJF) & Takeda Pharmaceutical (NYSE:TAK)
01:59am, Sunday, 26'th Jul 2026
Takeda Pharmaceutical (NYSE: TAK - Get Free Report) and Medicure (OTCMKTS:MCUJF - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses
Takeda Pharmaceutical (TAK) to Announce Quarterly Earnings on Thursday
02:27am, Thursday, 23'rd Jul 2026
Takeda Pharmaceutical (NYSE: TAK - Get Free Report) is anticipated to post its Q1 2027 results before the market opens on Thursday, July 30th. Analysts expect the company to post earnings of $0.1689 p
Takeda's QDENGA becomes first dengue vaccine approved in India
02:01am, Monday, 20'th Jul 2026
Japanese drugmaker Takeda Pharmaceutical's dengue vaccine QDENGA has been approved by India's drug regulator, making it the first dengue vaccine to be approved in the
Oral Psoriasis Drug From Takeda Demonstrates Strong Skin Clearance in Trials
01:08pm, Friday, 17'th Jul 2026
Takeda Pharmaceutical Co. Ltd. (NYSE:TAK) on Friday revealed encouraging secondary data from two pivotal Phase 3 trials evaluating zasocitinib, its next-generation oral treatment for moderate-to-sever
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and p
OSAKA, Japan & CAMBRIDGE, Mass. & JAKARTA, Indonesia--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and the Indonesian Government (the Ministry of Health, the Ministry of Investment and Downstream Indus
Insilico Medicine Announces Collaboration with Takeda to Advance Strategic AI Drug Discovery
10:16pm, Wednesday, 01'st Jul 2026
Partnership to leverage Pharma.AI platform for novel drug candidates across Takeda's therapeutic areas CAMBRIDGE, Mass., July 1, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico" HKEX:3696), a leade
Takeda, InSilico Strike AI Drug-Discovery Deal Worth Up to $600 Million
07:59pm, Wednesday, 01'st Jul 2026
Takeda is set to pay InSilico to use its proprietary Pharma. AI platform to advance drug candidates across several therapeutic areas, according to people familiar with the matter.
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
07:45am, Tuesday, 30'th Jun 2026
Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?
Takeda Announces New Assignments of Directors and Appointment of Julie Kim as Representative Director, President and CEO
03:05am, Wednesday, 24'th Jun 2026
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--In the final step of its 18-month CEO transition, Takeda (TOKYO:4502/NYSE:TAK) today announced that Julie Kim was officially appointed Takeda's Repres
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today presented additional results from two pivotal studies at SLEEP 2026, showing oveporexton (TAK-861), an oral orexin r
